Cano Health (CANO) Stock Forecast, Price Target & Predictions
CANO Stock Forecast
Cano Health stock forecast is as follows: an average price target of $6.42 (represents a 1505.00% upside from CANO’s last price of $0.40) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CANO Price Target
The average price target for Cano Health (CANO) is $6.42 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $1.25. This represents a potential 1505.00% upside from CANO's last price of $0.40.
CANO Analyst Ratings
According to 3 Wall Street analysts, Cano Health's rating consensus is 'Buy'. The analyst rating breakdown for CANO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cano Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 06, 2023 | - | UBS | $1.25 | $1.10 | 13.64% | 212.50% |
| Nov 16, 2022 | - | Citigroup | $5.00 | $2.04 | 144.79% | 1150.00% |
| May 10, 2022 | Jason Cassorla | Citigroup | $8.00 | $4.13 | 93.94% | 1900.00% |
| Apr 20, 2022 | - | UBS | $15.00 | $5.16 | 190.70% | 3650.00% |
| Mar 18, 2022 | Gary Taylor | Cowen & Co. | $13.00 | $6.99 | 85.98% | 3150.00% |
| Jan 14, 2022 | Jason Cassorla | Citigroup | $12.00 | $6.51 | 84.33% | 2900.00% |
The latest Cano Health stock forecast, released on Jan 06, 2023 by UBS company, set a price target of $1.25, which represents a 13.64% increase from the stock price at the time of the forecast ($1.10), and a 212.50% increase from CANO last price ($0.40).
Cano Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.40 | $0.40 | $0.40 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Cano Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cano Health's last price of $0.40. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 06, 2023 | UBS | - | Neutral | Downgrade |
| Nov 16, 2022 | Citigroup | Buy | Buy | Hold |
| Jun 24, 2022 | Raymond James | - | Outperform | Initialise |
| May 10, 2022 | Citigroup | Buy | Buy | Hold |
Cano Health's last stock rating was published by UBS on Jan 06, 2023. The company Downgrade its CANO rating from "null" to "Neutral".
Cano Health Financial Forecast
Cano Health Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $788.07M | $766.75M | $866.91M | $704.34M | $526.80M | $393.16M |
| Avg Forecast | $1.73B | $1.53B | $1.34B | $710.55M | $759.84M | $828.43M | $826.34M | $666.03M | $435.67M | $306.85M |
| High Forecast | $1.76B | $1.57B | $1.37B | $711.00M | $772.00M | $845.87M | $843.74M | $680.06M | $444.84M | $313.31M |
| Low Forecast | $1.71B | $1.52B | $1.33B | $710.10M | $742.40M | $820.37M | $818.30M | $659.55M | $431.43M | $303.86M |
| # Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | 1.04% | 0.93% | 1.05% | 1.06% | 1.21% | 1.28% |
Cano Health's average Quarter revenue forecast for Dec 23 based on 2 analysts is $710.55M, with a low forecast of $710.10M, and a high forecast of $711.00M. CANO's average Quarter revenue forecast represents a -9.84% decrease compared to the company's last Quarter revenue of $788.07M (Sep 23).
Cano Health EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | $-65.86M | $-142.09M | $-5.88M | $11.29M | $-33.60M | $25.12M |
| Avg Forecast | $38.65M | $34.35M | $30.06M | $15.92M | $17.02M | $18.56M | $18.51M | $27.79M | $-36.96M | $6.87M |
| High Forecast | $39.46M | $35.08M | $30.69M | $15.93M | $17.29M | $18.95M | $18.90M | $33.35M | $-29.57M | $7.02M |
| Low Forecast | $38.27M | $34.02M | $29.77M | $15.91M | $16.63M | $18.38M | $18.33M | $22.23M | $-44.36M | $6.81M |
| Surprise % | - | - | - | - | -3.87% | -7.66% | -0.32% | 0.41% | 0.91% | 3.65% |
1 analysts predict CANO's average Quarter EBITDA for Mar 23 to be $18.51M, with a high of $18.90M and a low of $18.33M. This is 63.89% upper than Cano Health's previous annual EBITDA (Mar 22) of $11.29M.
Cano Health Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | $-260.49M | $-140.75M | $-28.15M | $-85.00K | $-67.13M | $9.48M |
| Avg Forecast | $813.63M | $708.69M | $832.13M | $-100.29M | $-121.41M | $-47.51M | $-73.90M | $1.22M | $-73.84M | $-38.71M |
| High Forecast | $25.13B | $21.89B | $25.70B | $-5.81B | $-7.39B | $-1.47B | $-2.28B | $1.46M | $-59.07M | $-1.20B |
| Low Forecast | $43.42B | $37.82B | $44.40B | $-10.03B | $-12.14B | $-2.53B | $-3.94B | $975.52K | $-88.61M | $-2.07B |
| Surprise % | - | - | - | - | 2.15% | 2.96% | 0.38% | -0.07% | 0.91% | -0.24% |
Cano Health's average Quarter net income forecast for Sep 21 is $-73.84M, with a range of $-88.61M to $-59.07M. CANO's average Quarter net income forecast represents a -878.92% decrease compared to the company's last Quarter net income of $9.48M (Jun 21).
Cano Health SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | $80.82M | $99.42M | $96.47M | $96.59M | $75.93M | $46.57M |
| Avg Forecast | $258.60M | $229.87M | $201.13M | $106.51M | $113.90M | $124.18M | $123.87M | $178.45M | $83.52M | $46.00M |
| High Forecast | $264.05M | $234.71M | $205.37M | $106.58M | $115.72M | $126.79M | $126.48M | $214.14M | $100.22M | $46.96M |
| Low Forecast | $256.08M | $227.63M | $199.18M | $106.44M | $111.28M | $122.97M | $122.66M | $142.76M | $66.81M | $45.55M |
| Surprise % | - | - | - | - | 0.71% | 0.80% | 0.78% | 0.54% | 0.91% | 1.01% |
Cano Health's average Quarter SG&A projection for Dec 23 is $106.51M, based on 2 Wall Street analysts, with a range of $106.44M to $106.58M. The forecast indicates a 31.79% rise compared to CANO last annual SG&A of $80.82M (Sep 23).
Cano Health EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | $-91.87 | $-0.00 | $-0.12 | $-0.00 | $-0.09 | $0.06 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.19 | $-0.23 | $-0.09 | $-0.14 | $-0.10 | $-0.00 | $-0.07 |
| High Forecast | $47.61 | $41.47 | $48.69 | $-11.00 | $-14.00 | $-2.78 | $-4.32 | $-3.09 | $-0.05 | $-2.27 |
| Low Forecast | $82.25 | $71.64 | $84.12 | $-19.00 | $-23.00 | $-4.80 | $-7.47 | $-5.34 | $-0.08 | $-3.91 |
| Surprise % | - | - | - | - | 399.43% | 0.01% | 0.86% | 0.00% | 59.60% | -0.82% |
According to 1 Wall Street analysts, Cano Health's projected average Quarter EPS for Sep 21 is $-0.00, with a low estimate of $-0.08 and a high estimate of $-0.05. This represents a -102.52% decrease compared to CANO previous annual EPS of $0.06 (Jun 21).
Cano Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TOI | Oncology Institute | $0.29 | $8.00 | 2658.62% | Buy |
| CANO | Cano Health | $2.30 | $6.42 | 179.13% | Buy |
| AGL | agilon health | $3.64 | $5.50 | 51.10% | Buy |
| EHAB | Enhabit | $8.00 | $10.25 | 28.13% | Hold |
| AMEH | Astrana Health | $40.82 | $48.50 | 18.81% | Buy |
| SEM | Select Medical | $34.91 | $40.00 | 14.58% | Buy |
| INNV | InnovAge | $5.95 | $6.80 | 14.29% | Hold |
| ACHC | Acadia Healthcare Company | $77.77 | $84.89 | 9.16% | Buy |
| BKD | Brookdale Senior Living | $6.77 | $7.00 | 3.40% | Buy |
| UHS | Universal Health Services | $232.28 | $208.47 | -10.25% | Hold |
| PNTG | Pennant Group | $34.67 | $30.67 | -11.54% | Buy |
| ENSG | Ensign Group | $152.03 | $124.40 | -18.17% | Buy |
| THC | Tenet Healthcare | $156.96 | $124.87 | -20.44% | Buy |
CANO Forecast FAQ
Is Cano Health a good buy?
Yes, according to 3 Wall Street analysts, Cano Health (CANO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of CANO's total ratings.
What is CANO's price target?
Cano Health (CANO) average price target is $6.42 with a range of $1.25 to $13, implying a 1505.00% from its last price of $0.4. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cano Health stock go up soon?
According to Wall Street analysts' prediction for CANO stock, the company can go up by 1505.00% (from the last price of $0.4 to the average price target of $6.42), up by 3150.00% based on the highest stock price target, and up by 212.50% based on the lowest stock price target.
Can Cano Health stock reach $1?
CANO's average twelve months analyst stock price target of $6.42 supports the claim that Cano Health can reach $1 in the near future.
What are Cano Health's analysts' financial forecasts?
CANO's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $3.13B (high $3.17B, low $3.09B), average EBITDA is $70.01M (high $71.07M, low $69.25M), average net income is $-343M (high $-16.946B, low $-28.648B), average SG&A $468.46M (high $475.57M, low $463.36M), and average EPS is $-0.65 (high $-32.104, low $-54.273).
Did the CANO's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Sep 2023), Cano Health's revenue was $788.07M, beating the average analysts' forecast of $759.84M by 3.72%. The company's EBITDA was $-65.859M, missing the average prediction of $17.02M by -486.91%. Cano Health's net income was $-260M, beating the average estimation of $-121M by 114.56%. The company's SG&A was $80.82M, missing the average forecast of $113.9M by -29.04%. Lastly, the company's EPS was $-91.87, beating the average prediction of $-0.23 by 39843.48%